undefined
EUTM file information

018557419

Haematox


September 12, 2021

Trademark Summary

The trademark Haematox was filed by HAEMATO AG, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on January 26, 2022, and received one opposition filed on February 10, 2022 by Haemochrom Diagnostica GmbH on Likelihood of confusion. the opponent was represented by Karst, Andreas and proceedings were handled in German, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued February 10, 2022

The application was filed in German, and German was also language of all opposition proceedings (English was selected as the second language).

The Opposition with reference B 003163781 was Reject opposition: opposition not admissible according to Article 8(1)(b) EUTMR with decision issued on August 24, 2022 by the EUIPO.


Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Botulinum toxin
    2. Pharmaceutical preparations, for use in the following fields: Treatment of tics
    3. Pharmaceutical preparations for the treatment of muscular dystrophy
    4. Pharmaceutical preparations, for use in the following fields: Treatment of dystonia
    5. Pharmaceutical preparations, for use in the following fields: Treatment of cerebral palsy
    6. Pharmaceutical preparations for the treatment of hyperhidrosis
    7. Pharmaceutical preparations for the treatment of headaches
    8. Pharmaceutical preparations, for use in the following fields: Treatment of tremors
    9. Pharmaceutical preparations for treating sports injuries
    10. Pharmaceutical preparations for treating neurodegenerative diseases
    11. Pharmaceutical preparations for the treatment of neurological disorder
    12. Pharmaceutical preparations, for use in the following fields: Treatment of autonomic imbalances
    13. Pharmaceutical preparations for the treatment of wrinkles
    14. Pharmaceuticals for the treatment of pain
    15. Pharmaceutical preparations for treatment of smooth muscle disease
    16. None of the aforesaid pharmaceutical preparations for diagnostic analytical purposes, not for experimental purposes and not for laboratory and research purposes.